Q3 2025 Earnings Call Transcript October 30, 2025 Merit Medical Systems, Inc. beats earnings expectations. Reported EPS is $0 ...

Dr. Vipulroy Rathod, leading gastroenterologist in Mumbai, pioneers advanced minimally invasive endoscopy (EUS, ERCP) for ...

Merit Medical Systems, Inc. MMSI reported third-quarter 2025 adjusted earnings per share (EPS) of 92 cents, up 6.9% from the ...

Imagine a surgeon in the middle of a complex operation, able to get instant biochemical feedback not from a lab down the hall ...

Mucoceles are benign sinus tumors that are caused by an obstruction in the sinus ostium. We report 3cases managed at the University Hospital of Kamenge, where treatment was surgical via an endoscopic ...

Discover Merit Medical Systems’ Q3 2025 earnings highlights—record margins, revenue growth, and strategic outlook under new CEO leadership.

Medical device company Merit Medical Systems (NASDAQ:MMSI) announced better-than-expected revenue in Q3 CY2025, with sales up ...

Highlights† Reported revenue of $384.2 million, up 13.0%Constant currency revenue* and constant currency revenue, organic* up 12.5% and up 7.8%, ...

Return on Equity (ROE): Merit Medical Systems's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 2.23%, the company showcases efficient ...

Whether selective decontamination of the digestive tract (SDD) reduces mortality among patients undergoing mechanical ...

Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Small Cap Growth Fund” third-quarter ...

Icotrokinra demonstrated clinically meaningful outcomes at Week 28 in the Phase 2b ANTHEM-UC study in ulcerative colitis, with 31.7% of patients achieving clinical remission and 38.1% showing ...